This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Ronald W. Ellis, PhD; R. Gordon Douglas, Jr, MD

JAMA. 1994;271(12):929-931.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

PREVENTION of disease is a tenet of all the various approaches to health care reform. One of the most effective medical interventions ever devised are vaccines, with their high level of benefit and cost-effectiveness for public health. There has never been a more exciting time for vaccine research and development, largely as a result of the implementation and refinement of a variety of new technologies. Several new vaccines have been licensed recently in different countries for routine use, including recombinant hepatitis B (HB), Haemophilus influenzae type b (Hib) conjugate, and hepatitis A (HA) vaccines. Several more are expected to be licensed throughout the 1990s, including acellular pertussis (for infants), varicella, and pneumococcal conjugate vaccines. Of potentially greater importance are several technological developments that, if successful, would revolutionize the way in which vaccines are produced and used. This article reviews three such developments, each of which is being researched and developed . . . [Full Text PDF of this Article]

Author Affiliations
From Merck Research Laboratories, West Point, Pa (Dr Ellis) and Merck Vaccine Division (Dr Douglas), Merck & Co Inc, Whitehouse Station, NJ.

Footnotes
Reprint requests to Merck Research Laboratories, Bldg 16, Room 101, Merck & Co, Sumneytown Pike, West Point, PA 19486 (Dr Ellis).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?